natgillin/translations-raw huggingface dataset:
• Inability to control your bowel movements.
• nemogućnost kontrole stolice.
Vandetanib also inhibited the growth of MTC xenograft tumours in vivo.
Vandetanib je inhibirao i rast ksenotransplantata medularnog karcinoma štitnjače in vivo.
Dose adjustments in paediatric patients with MTC
Prilagodbe doze u pedijatrijskih bolesnika s medularnim karcinomom štitnjače
• Inflammation of the voice box (larynx).
• upala ždrijela (larinksa).
• Swelling of the brain.
• oticanje mozga.
Interstitial Lung Disease (ILD) has been observed in patients receiving vandetanib and some cases have been fatal.
U bolesnika koji primaju vandetanib zabilježena je intersticijska bolest pluća, koja je u nekim slučajevima završila smrću.
Five out of 6 patients (83%) with moderate renal failure who were treated with vandetanib had a dose reduction to 200 mg for adverse reaction; 1 patient required a further reduction to 100 mg.
U 5 od 6 bolesnika (83%) s umjerenim zatajenjem bubrega koji su liječeni vandetanibom, doza je zbog nuspojave smanjena na
• If you may become pregnant you must use effective contraception when you are taking Caprelsa and for at least four months after the last dose of Caprelsa.
• Ako možete zatrudnjeti, morate koristiti učinkovitu kontracepciju tijekom uzimanja lijeka
Posology for MTC in adult patients
Doziranje za medularni karcinom štitnjače u odraslih bolesnika
Caprelsa is a treatment for adults and children aged 5 years and above with: Medullary thyroid cancer that cannot be removed by surgery or has spread to other parts of the body.
medularnim karcinomom štitnjače koji se ne može odstraniti operacijom ili se proširio na druge dijelove tijela.
Increase of serum ALT and AST, weight decreased blood creatinine increased
Pretrage produljenje QTc intervala na EKG-u povišene vrijednosti ALT-a i AST-a u serumu, smanjenje tjelesne težine, povišene vrijednosti kreatinina u krvi povišene vrijednosti hemoglobina, povišene vrijednosti amilaza u serumu
• Boil.
• bol.
The Caprelsa 300 mg tablet is an oval-shaped, biconvex, white film-coated tablet with ‘Z300' impressed on one side.
Caprelsa 300 mg tableta je ovalna, bikonveksna, bijela filmom obložena tableta, s utisnutom oznakom ‘Z300' na jednoj strani.
QTc and serum electrolytes should be monitored more frequently.
QTc-interval i razinu elektrolita u serumu.
Medicinal products known to prolong QTc interval Vandetanib has been shown to prolong the ECG QTc interval; Torsades de pointes have been uncommonly reported.
Pokazalo se da vandetanib produljuje QTc-interval, a manje često su prijavljeni slučajevi torsades de pointes.
• Inflammation of the pancreas (pancreatitis).
• upala gušterače (pankreatitis).
The Caprelsa 100 mg tablet is a round, biconvex, white film-coated tablet with ‘Z100' impressed on one side.
Caprelsa 100 mg tableta je okrugla, bikonveksna, bijela filmom obložena tableta, s utisnutom oznakom ‘Z100' na jednoj strani.
Epistaxis, haemoptysis, pneumonitis
Poremećaji dišnog sustava, prsišta i sredoprsja epistaksa, hemoptiza, pneumonitis zatajenje disanja, aspiracijska pneumonija
• Inflammation of the nasal passages.
• upala nosnih puteva.
• Decreased levels of sodium in your blood.
• smanjena razina natrija u krvi.
Alanine aminotransferase elevations occur commonly in patients treated with vandetanib.
U bolesnika liječenih vandetanibom često dolazi do povišenja razina alanin aminotransferaze.
• Dizziness.
• nesvjestica.
• Nose bleed (epistaxis).
• krvarenje iz nosa (epistaksa).
Ocular events such as blurred vision are common in patients who received vandetanib for MTC.
Nuspojave oka poput zamagljenog vida javljaju se često u bolesnika liječenih vandetanibom zbog medularnog karcinoma štitnjače.
• Decrease in thyroid function.
• smanjena funkcija štitnjače.
• Tiredness.
• mučnina.
Caprelsa 300 mg is a white oval-shaped film-coated tablet with “Z300” imprinted on one side.
Caprelsa 300 mg je bijela, ovalna filmom obložena tableta s utisnutom oznakom ‘Z300' na jednoj strani.
Therefore, no change in dose of vandetanib is required when vandetanib is given with either omeprazole or ranitidine.
AUC(0-t) vandetaniba kada se davao zajedno s ranitidinom.Stoga nije potrebna promjena doze vandetaniba kada se daje bilo s omeprazolom ili ranitidinom.
• Inflammation of the sinuses.
• upala sinusa.
NAME OF THE MEDICINAL PRODUCT Caprelsa 100 mg film-coated tablets vandetanib
Caprelsa 100 mg filmom obložene tablete vandetanib
Chromaturia, anuria
mučnina, povraćanje,
INFORMATION IN BRAILLE Caprelsa 300 mg
Caprelsa 300 mg
• Vandetanib was found not to impair linear growth in clinical trials conducted in children and adolescents;
• U kliničkim ispitivanjima u djece i adolescenata utvrđeno je da vandetanib ne smanjuje linearni rast;
• Pain.
• zamor.
What Caprelsa contains
Kako Caprelsa izgleda i sadržaj pakiranja
NAME OF THE MEDICINAL PRODUCT Caprelsa 300 mg film-coated tablets vandetanib
Caprelsa 300 mg filmom obložene tablete vandetanib
INFORMATION IN BRAILLE Caprelsa 100 mg
Caprelsa 100 mg
• Dry mouth.
• suha usta.
Hypertension, including hypertensive crisis, has been observed in patients treated with vandetanib.
U bolesnika liječenih vandetanibom zabilježena je hipertenzija, uključujući i hipertenzivnu krizu.
Visual impairment, halo vision, photopsia, glaucoma, conjunctivitis, dry eye, keratopathy
aureole oko izvora svjetlosti, fotopsija, glaukom, konjunktivitis,
Photosensitivity reaction, rash and other skin rections (including acne, dry skin, dermatitis, pruritus), nail disorders
(uključujući akne, suhu kožu, dermatitis, svrbež),
NAME OF THE MARKETING AUTHORISATION HOLDER Genzyme Europe B.V.
Genzyme Europe B.V.
Vision blurred, corneal structural change (including corneal deposits and corneal opacity)
Poremećaji oka zamagljen vid, strukturna promjena rožnice
Cholelithiasis
Proljev
Norge sanofi-aventis Norge AS
Ireland sanofi-aventis Ireland Ltd.
Proteinuria, nephrolithiasis
Prijavljivanje nuspojava
Renal impairment in adult patients with MTC
Oštećenje bubrega u odraslih bolesnika s medularnim karcinomom štitnjače
Individual patient management will be required by the physician, especially in paediatric patients with low BSA.
posebno za pedijatrijske bolesnike s malom površinom tijela.
• Drowsiness.
• pospanost.
How to store Caprelsa
Moguće nuspojave Kako čuvati Caprelsu
• Visual impairment.
• poremećaj vida.
• No change in starting dose is recommended in paediatric patients with mild renal impairment
• za pedijatrijske bolesnike s blagim oštećenjem bubrega nije preporučena nikakva promjena početne doze;
• Tremor.
• umor.
Vandetanib treatment must not be started in patients whose ECG QTc interval is greater than 480 msec. Vandetanib should not be given to patients who have a history of Torsades de pointes.
Liječenje vandetanibom ne smije se započeti u bolesnika koji imaju na EKG-u
Posology in paediatric patients with MTC
Doziranje u pedijatrijskih bolesnika s medularnim karcinomom štitnjače
Caprelsa 300 mg film-coated tablets
Caprelsa 100 mg filmom obložene tablete Caprelsa 300 mg filmom obložene tablete
• Fever.
• vrućica.
Renal impairment in paediatric patients with MTC There is no experience with the use of vandetanib in paediatric patients with renal impairment.
Nema iskustva s primjenom vandetaniba u pedijatrijskih bolesnika s oštećenjem bubrega.
• Decreased levels of potassium in your blood.
• smanjena razina kalija u krvi.
Heart failure has been observed in patients who received vandetanib.
U bolesnika liječenih vandetanibom zabilježeno je zatajenje srca.
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 100 mg vandetanib.
Jedna tableta sadrži 100 mg vandetaniba.
If another event of common terminology criteria for adverse events (CTCAE) grade 3 or higher toxicity or prolongation of the ECG QTc interval occurs, dosing with Caprelsa should be at least temporarily stopped and resumed at a reduced dose (c in Table 1) when toxicity has resolved or improved to CTCAE grade 1.
Caprelsa treba barem privremeno prekinuti te nastaviti u sniženoj dozi (c u Tablici 1) nakon što se toksični učinci povuku ili umanje do CTCAE stupnja 1. • Ako dođe do još događaja CTCAE stupnja 3 ili višeg, toksičnosti ili produljenja QTc intervala na EKG-u, primjenu vandetaniba treba trajno prekinuti.
Abdominal pain, diarrhoea, nausea, vomiting, dyspepsia
Poremećaji probavnog sustava bol u abdomenu, proljev,
• Urinary tract infections.
• infekcije mokraćnih puteva.
NAME OF THE MEDICINAL PRODUCT Caprelsa 100 mg tablets vandetanib
Caprelsa 100 mg tablete vandetanib
Dysuria, hematuria, renal failure, pollakiuria, micturition urgency
Poremećaji bubrega i mokraćnog sustava proteinurija, nefrolitijaza dizurija, hematurija, zatajenje bubrega, polakizurija, hitni nagon za mokrenjem kromaturija, anurija
• Abdominal pain.
• opstrukcija crijeva.
Slovenija sanofi-aventis d.o.o.
UAB „SANOFI-AVENTIS LIETUVA“
NAME OF THE MEDICINAL PRODUCT Caprelsa 300 mg tablets vandetanib
Caprelsa 300 mg tablete vandetanib
• They are aged over 55 years with new or recently changed symptoms.
• je stariji je od 55 godina i ima nove ili nedavno promijenjene simptome.
Do not exceed this dose.
Ne prekoračujte ovu dozu.
Interference with Laboratory Tests
Interferencija s laboratorijskim testovima
Take the tablet before a meal, at the same time every day.
Tabletu uzimajte prije obroka, svaki dan u isto vrijeme.
Some of this increase may be due to other risk factors.
Neka od ovih povećanja mogu biti zbog utjecaja drugih čimbenika rizika.
You should not take it as a preventive measure.
Ne smijete ga uzimati kao preventivnu mjeru.
The following additional risks are considered relevant for long-term use:
Sljedeći dodatni rizici smatraju se relevantnim pri dugotrajnoj primjeni:
Patients should be instructed to consult a doctor if:
Bolesnika se mora uputiti da se obrati liječniku ako:
Take your next, normal dose, the next day, at your usual time.
Uzmite sljedeću redovitu dozu sljedeći dan u uobičajeno vrijeme.
Do not chew or break the tablet.
Nemojte žvakati ili lomiti tabletu.
• They have any other serious disease affecting general well-being.
• ima neku drugu ozbiljnu bolest koja utječe na njegovo dobro opće stanje.
Approximately 5% of patients can be expected to experience adverse reactions.
Očekuje se da će otprilike 5% bolesnika osjetiti nuspojave.
On short-term use, in most cases they do not exceed the upper limit of normal.
U slučaju kratkotrajne primjene te vrijednosti u većini slučajeva ne prelaze gornju granicu normale.
If possible take your medicine and this leaflet with you.
Ako je moguće ponesite lijek i ovu Uputu sa sobom.
The slight increase in AUC and Cmax in elderly volunteers compared with younger subjects was not clinically relevant.
Manje povećanje AUC i Cmax kod starijih dobrovoljaca u odnosu na mlađe ispitanike nije bilo klinički značajno.
You should not take this medicine if you are pregnant or while-breastfeeding.
Ovaj lijek ne smijete uzimati ako ste trudni ili dojite.
HIV-infection).
HIV-om).
Ask your pharmacist how to throw away medicines you no longeruse.
Pitajte svog ljekarnika kako baciti lijekove koje više ne koristite.
This medicinal product is intended for short-term use (up to 4 weeks) only (Refer to section 4.2).
Ovaj lijek namijenjen je samo za kratkotrajnu primjenu (do 4 tjedna) (vidjeti dio 4.2).
The absolute bioavailability from the tablet was found to be about 77%.
Apsolutna bioraspoloživost iz tablete iznosi oko 77%.
Take one tablet (20 mg) per day.
Uzmite jednu tabletu (20 mg) na dan.
Tell your doctor immediately or contact the casualty department at your nearest hospital, if you get any of the following serious side effects.
Odmah obavijestite svog liječnika ili se uputite u najbližu bolnicu ako dobijete bilo koju od sljedećih ozbiljnih nuspojava.
The relevance of this finding to the paediatric population is unclear.
Značaj ovog opažanja za pedijatrijsku populaciju nije jasan.
Tablets should be swallowed whole.
Tabletu treba progutati cijelu.
You should swallow the tablet whole with some water.
Tabletu morate progutati cijelu s nešto vode.
Hence it reduces the amount of acid in your stomach.
Stoga smanjuje sadržaj kiseline u Vašem želucu.
There were no interactions with concomitantly administered antacids.
Nije bilo interakcija s istodobno uzimanim antacidima.
The increase in gastrin is reversible.
Povećana razina gastrina je reverzibilna.
In the case of overdose with clinical signs of intoxication, apart from symptomatic and supportive treatment, no specific therapeutic recommendations can be made.
U slučaju predoziranja s kliničkim znakovima intoksikacije, osim simptomatskog i potpornog liječenja, nema specifičnih terapijskih preporuka.
Doses up to 240 mg administered intravenously over 2 minutes were well tolerated.
Doze do 240 mg primjenjivane intravenski tijekom 2 minute dobro su se podnosile.
- Ask your pharmacist if you need more information or advice.
- Obratite se ljekarniku ako trebate dodatne informacije ili savjet.
Distribution Volume of distribution is about 0.15 l/kg and serum protein binding is about 98%.
Distribucija Volumen distribucije je oko 0,15 l/kg, a vezanje za proteine seruma je oko 98%.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity.
Neklinički podaci ne ukazuju na posebnu opasnost za ljude na temelju konvencionalnih ispitivanja sigurnosne farmakologije, toksičnosti ponovljenih doza i genotoksičnosti.
The most commonly reported adverse reactions are diarrhoea and headache, both occuring in approximately 1% of patients.
Najčešće prijavljene nuspojave su proljev i glavobolja, koje se javljaju u otprilike 1% bolesnika.
Date of first authorisation: 12 June 2009 Date of latest renewal: 21 February 2014
Datum posljednje obnove odobrenja: 21. veljače 2014.
As with healthy subjects, the half-life of pantoprazole is short.
Kao i kod zdravih ispitanika, poluvijek pantoprazola je kratak.
You must talk to a doctor if you do not feel better or if you feel worse after 2 weeks.
Obavezno se obratite liječniku ako se ne osjećate bolje ili ako se osjećate lošije nakon 2 tjedna.
Your doctor may decide to perform regular blood tests to monitor your levels of magnesium.
Vaš liječnik se može odlučiti da je potrebno provoditi redovite krvne pretrage kako bi se nadzirala razina magnezija u krvi.
Pharmacokinetics do not vary after single or repeated administration.
Farmakokinetika se ne mijenja nakon jednokratne ili ponovljene primjene.
HIV Protease Inhibitors
Inhibitori HIV proteaze
What PANTOLOC Control is and what it is used for
Što je PANTOLOC Control i za što se koristi
Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist have told you.
Uvijek uzmite ovaj lijek točno onako kako je opisano u ovoj uputi ili kako su Vam je rekao liječnik ili ljekarnik.
The effect of pantoprazole on newborns/infants is unknown.
Učinak pantoprazola na novorođenčad/dojenčad nije poznat.
Your doctor may decide that you need some tests.
Liječnik će odlučiti jesu li potrebne neke pretrage.
The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.
Nositelj odobrenja će periodička izvješća o neškodljivosti za ovaj lijek podnositi u skladu s referentnim popisom datuma EU (EURD popis) predviđenim člankom 107.c stavkom 7 Direktive 2001/83/EZ i objavljenim na europskom internetskom portalu za lijekove.
Low levels of magnesium can also lead to a reduction in potassium or calcium levels in the blood.
Niske razine magnezija mogu također dovesti do smanjenja razina kalija ili kalcija u krvi.
However, an interaction of pantoprazole with other substances which are metabolised by the same enzyme system cannot be excluded.
Međutim, interakcije pantoprazola s drugim lijekovima koji se metaboliziraju istim enzimskim sustavom se ne mogu isključiti.
If you take PANTOLOC Control for longer periods, this may cause additional risks, such as:
Uzimanje lijeka Pantoloc Control tijekom duljih razdoblja može izazvati dodatne rizike, kao što su:
To avoid this interference, PANTOLOC Control treatment should be stopped for at least 5 days before CgA measurements (see section 5.1).
Kako bi se izbjegla ova interferencija, liječenje lijekom PANTOLOC Control potrebno je prekinuti najmanje 5 dana prije mjerenja razine CgA (vidjeti dio 5.1.).
PANTOLOC Control has no or negligible influence on the ability to drive and use machines.
PANTOLOC Control ne utječe ili neznatno utječe na sposobnost upravljanja vozilima ili rada sa strojevima.
PANTOLOC Control is not recommended for use in children and adolescents below 18 years of age due to insufficient data on safety and efficacy.
PANTOLOC Control se ne preporučuje za primjenu u djece i adolescenata u dobi ispod 18 godina jer nema dovoljno podataka o sigurnosti i djelotvornosti.
If you are due to have a blood test, tell your doctor that you are taking this medicine.
Ukoliko idete na krvne pretrage, obavijestite liječnika da uzimate ovaj lijek.
Patients should be warned about additional risks with long-term use of the medicinal products and the need for prescription and regular surveillance should be emphasized.
Bolesnike treba upozoriti na dodatne rizike dugotrajnog uzimanja lijekova i naglasiti nužnost propisivanja i redovitog nadzora.
However, adverse reactions such as dizziness and visual disturbances may occur (see section 4.8).
Međutim, mogu se pojaviti nuspojave poput omaglice i poremećaja vida (vidjeti dio 4.8).
If you take more PANTOLOC Control than you should Tell your doctor or pharmacist if you have taken more than the recommended dose.
Ako uzmete lijeka PANTOLOC Control nego što ste trebali Obavijestite liječnika ili ljekarnika ako ste uzeli više od preporučene doze.
PANTOLOC Control may stop certain other medicines from working properly.
PANTOLOC Control može zaustaviti djelovanje nekih drugih lijekova.
Hallucination; Confusion (especially in pre-disposed patients, as well as the aggravation of these symptoms in case of pre-existence)
halucinacije; konfuzija (posebno u predisponirani h bolesnika, kao i pogoršanje tih simptoma ako su već bili prisutni)
Once complete relief of symptoms has occurred, treatment should be discontinued.
Kad se simptomi potpuno povuku, liječenje se mora prekinuti.
Patients should be advised that the tablets are not intended to provide immediate relief.
Bolesnike se mora upozoriti da tablete ne donose trenutno olakšanje tegoba.
Within the following table, adverse reactions are ranked under the MedDRA frequency classification: Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data).
Unutar sljedeće tablice nuspojave su razvrstane prema MedDRA klasifikaciji učestalosti: Vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
In the 2-year carcinogenicity studies in rats, neuroendocrine neoplasms were found.
U 2-godišnjim ispitivanjima karcinogenosti kod štakora nađene su neuroendokrine neoplazme.
Biotransformation Pantoprazole is almost exclusively metabolized in the liver.
Biotransformacija Pantoprazol se metabolizira gotovo isključivo u jetri.
D-16515 Oranienburg Germany
16515 Oranienburg Njemačka
PANTOLOC Control 20 mg gastro-resistant tablets should not be chewed or crushed, and should be swallowed whole with liquid before a meal.
PANTOLOC Control 20 mg želučanootporne tablete se ne smiju žvakati ni lomiti, već ih se mora progutati cijele s tekućinom prije obroka.
OUTER CARTON FOR BLISTER OUTER CARTON FOR BLISTER WITH CARDBOARD REINFORCEMENT
KUTIJA ZA BLISTER KUTIJA ZA BLISTER S KARTONSKIM POJAČANJEM
Influence on Vitamin B12 Absorption
Utjecaj na apsorpciju vitamina B12
The half-life of the main metabolite (about 1.5 h) is not much longer than that of pantoprazole.
Poluvijek glavnog metabolita (oko 1,5 h) nije značajno dulji od poluvijeka pantoprazola.
Pantoprazole was consistently shown to be superior to placebo and H2RA and non-inferior to other PPIs.
Pantoprazol se dosljedno pokazivao superiornim placebu i H2RA i neinferiornim u odnosu na ostale IPP-e.
Although the main metabolite has a longer half-life (2-3h), excretion is still rapid and thus accumulation does not occur.
Iako glavni metabolit ima dulji poluvijek (2-3 h), izlučivanje je i dalje brzo te ne dolazi do akumulacije.
GORD diagnosis in these studies was based on endoscopic assessment, with the exception of one study in which the inclusion of the patients was based on symptomatology alone.
Dijagnoza GERB-a temeljila se na endoskopskoj procjeni, osim kod jednog ispitivanja u koje su bolesnici uključeni samo na osnovi simptomatologije.
A previous peri-postnatal study in rats at slightly lower doses found no adverse effects at 3 mg/kg compared with a low dose of 5 mg/kg in this study.
U prethodnom peri- postnatalnom ispitivanju u štakora u nešto nižim dozama nisu zabilježeni štetni učinci pri 3 mg/kg, u usporedbi s niskom dozom od 5 mg/kg u ovom ispitivanju
PANTOLOC Control is available in Alu/Alu blisters with or without cardboard reinforcement.
PANTOLOC Control je dostupan u Al/Al blisterima sa ili bez kartonskog pojačanja.
What PANTOLOC Control is and what it is used for What you need to know before you take PANTOLOC Control How to take PANTOLOC Control Possible side effects
Što je PANTOLOC Control i za što se koristi Što morate znati prije nego počnete uzimati PANTOLOC Control Kako uzimati PANTOLOC Control Moguće nuspojave
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/.
Detaljne informacije o ovom lijeku dostupne su na web stranici Europske agencije za lijekove: http://www.ema.europa.eu/
StevensJohnson syndrome; Lyell syndrome;
StevensJohnsonov sindrom;
However, according to the studies conducted so far, the formation of carcinoid precursors (atypical hyperplasia) or gastric carcinoids as were found in animal experiments (see section 5.3) have not been observed in humans.
Međutim, prema dosadašnjim ispitivanjima, stvaranje karcinoidnih prekursora (atipičnih hiperplazija) ili gastričkih karcinoida kakvi su nađeni u pokusima na životinjama (vidjeti dio 5.3) nije opaženo kod ljudi.
For the complete relief from acid regurgitation, similar results were obtained as for heartburn.
Za potpuni nestanak regurgitacije kiseline dobiveni su slični rezultati kao i za žgaravicu.
How to store PANTOLOC Control Contents of the pack and other information
Kako čuvati PANTOLOC Control Sadržaj pakiranja i druge informacije
There are no adequate data from the use of pantoprazole in pregnant women.
Nema odgovarajućih podataka o primjeni pantoprazola u trudnica.
Stop taking PANTOLOC Control when you are completely symptom-free.
Prestanite uzimati PANTOLOC Control kada nastupi potpuno povlačenje simptoma.
The main metabolite in both serum and urine is desmethylpantoprazole, which is conjugated with sulphate.
Glavni metabolit u serumu i urinu je desmetilpantoprazol koji je konjugiran sa sulfatom.
- if you get a rash on your skin, especially in areas exposed to the sun tell your doctor as soon as you can, as you may need to stop your treatment with PANTOLOC Control.
- Ako dobijete osip na koži, posebice na područjima izloženima suncu obavijestite svojeg liječnika što je prije moguće, jer ćete možda morati prekinuti liječenje PANTOLOC Control.
After administration of pantoprazole to patients with liver impairment (Child-Pugh classes A, B and C) the half-life values increased to between 3 and 7 h and the AUC values increased by a factor of 3-6, whereas the Cmax only increased slightly by a factor of 1.3 compared with healthy subjects.
Nakon primjene pantoprazola u bolesnika s oštećenjem jetre (Child-Pugh stadiji A, B i C) vrijednosti poluvijeka se povećavaju na između 3 i 7 sati, a vrijednosti AUC se povećavaju za faktor 3-6, dok se Cmax povećava samo za faktor 1,3 u usporedbi sa zdravim ispitanicima.